BridgeBio to Participate in November and December Investor Conferences
BridgeBio Pharma (BBIO) announced that management will participate in fireside chats at four healthcare investor conferences in November and December 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BridgeBio Pharma (BBIO) announced that management will participate in fireside chats at four healthcare investor conferences in November and December 2026.
Appearances are scheduled at Jefferies on November 16, Evercore ISI on November 30, Citi on December 1 and Piper Sandler on December 2. Live webcasts will be accessible through the company’s investor website, with replays available for 30 days following each event.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its management team will participate in fireside chats at the following healthcare investor conferences:
- Jefferies Global Healthcare Conference, London, UK: Monday, November 16 at 9:30 am GMT
- Evercore ISI 9th Annual Healthcare Conference, Miami, FL: Monday, November 30 at 2:35 pm EST
- Citi Global Healthcare Conference 2026, Miami, FL: Tuesday, December 1 at 3:00 pm EST
- Piper Sandler 38th Annual Healthcare Conference, New York, NY: Wednesday, December 2 at 9:30 am EST
To access the live webcast of BridgeBio’s presentations, please visit the “Events and Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com. A replay of the webcasts will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, YouTube, and TikTok.
BridgeBio Media Contact:
Kaitlyn Reilly, Director, Communications
contact@bridgebio.com
(650)-789-8220
BridgeBio Investor Contact:
BridgeBio Investor Relations
ir@bridgebio.com
